A Novel Formulation
Engineered for the CNS
Engineered for Targeted Central Nervous System Delivery
Zy Therapeutics is partnering with Industry-leading formulation scientists to engineer Kamini® for Targeted Central Nervous System Delivery.
Each ZY-001 (Kamini®) microgranule features a three-layer architecture designed for safe, efficient intestinal absorption, and enhanced CNS exposure:
Micro-Encapsulated Core
Contains purified disodium etidronate for controlled release.
Penetration Enhancer Layer
Incorporates permeability agents (e.g., sodium caprate or lipid excipients) to facilitate transit across the blood-brain barrier.
Enteric Coating
Protects the drug through the stomach and releases it in the proximal jejunum—the optimal absorption site—while reducing gastrointestinal irritation historically observed with Didronel®.
Together, these innovations are designed to achieve increased bioavailability and a significantly improved tolerability profile.
A Patient-Centric, Personalized Approach
ZY-001 is designed as a sachet / stick pack formulation (Kamini® microgranules). This modern, flexible design allows for precise, weight-based dosing that can be tailored to the specific needs of each patient, from children to adults.
This user-friendly format represents a true personalized medicine approach, ensuring tolerability and simplifying administration for families and caregivers.